The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently approved DLBCL drug.
Jazz Pharmaceuticals is paying Zymeworks $50 million up front for rights to develop zanidatamab, a bispecific antibody cancer currently in two pivotal clinical trials. It’s the second bispecific antibody pact of the week, following Gilead Sciences’ deal to secure an option on a MacroGenics drug in early clinical development.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Artificial intelligence and machine learning are key to 3T Biosciences’ approach to identifying novel drug targets and engineering better, safer cancer immunotherapies. The Stanford spinout is now out of stealth with a $40 million Series A financing and a plan to reach the clinic within two years.
Follicular lymphoma patients in Europe now have a new treatment option. The European Commission approved Roche drug Lunsumio, a bispecific antibody designed to go after two targets to treat advanced cases of this type of cancer.
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.
It remains unclear how many patients will relapse without the BCMA antigen, which would complicate their ability to use many CAR-T cell therapies later on. However, an expert said the drug's safety could be a challenge.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The hold had been placed in February following two deaths in the study, including one in a patient who experienced cytokine release syndrome. The company has amended the trial protocol to mandate monitoring and management of CRS.
The company sees its platform as potentially overcoming off-target toxicities in existing antibody-drug conjugates, bispecific antibodies and solid tumor CAR-Ts.